List view / Grid view

Gilead Sciences


FDA approves Epclusa for treatment of chronic HCV

29 June 2016 | By Victoria White, Digital Content Producer

Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection...

Send this to a friend